Oropharyngeal Cancer Archives - Page 3 of 5

The confluence of the basket study design and genomic sequencing is speeding delivery of targeted tr

General Oncology

New Staging System for HPV-positive Oropharyngeal Cancer Proposed

By

Lourdes Briz

February 29, 2016

The ICON-S developed a TNM classification specific to human papillomavirus (HPV)-related oropharyngeal cancer.

Head and Neck Cancer

HPV-16 in Oral Cavity Associated With Increased Risk of Oropharyngeal Squamous Cell Carcinoma

By

John Schieszer, MA

January 28, 2016

Detection of human papillomavirus (HPV)-16 in the oral cavity may be associated with 22-times increased risk of oropharyngeal squamous cell carcinoma.

Head and Neck Cancer

HPV16+ Patients With Oropharyngeal Squamous Cell Cancer Survive Longer Than HPV- Patients

By

Jason Hoffman, PharmD, RPh

November 20, 2015

Human papillomavirus 16 (HPV16)-positive patients with oropharyngeal squamous cell cancer (OPSCC) survive longer than HPV-negative patients.

Head and Neck Cancer

Veterans May Face Poorer Oral, Throat Cancer Outcomes

August 24, 2015

In veterans, oropharyngeal squamous cell carcinoma (SCC) is associated with traditional carcinogens and poor clinical outcomes.

Human papillomavirus type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for

Head and Neck Cancer

HPV16 DNA Rinse Post Treatment Could Predict Recurrence

By

Lourdes Briz

July 31, 2015

Human papillomavirus (HPV) type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for HPV oropharyngeal carcinoma (OPC).

Elective neck dissection in clinically node-negative early oral squamous cell carcinoma should be co

Head and Neck Cancer

Cost Burdens on Patients Older than 66 with Oral Cavity, Pharyngeal Cancers

July 15, 2015

Several factors associated with the burdensome Medicare cost of oral and pharyngeal cancer in older patients.

Head and Neck Cancer

In Teen Boys, HPV4 Vaccine Cost-Effective for Oropharyngeal Prevention

April 14, 2015

The quadrivalent human papillomavirus (HPV4) vaccine appears to be cost-effective for the prevention of oropharyngeal cancer (OPC).

Reduced-dose Radiation Safe for Certain Patients with Low-risk HPV-positive Oropharyngeal Cancer

From The Advisory Board

Treatment Deintensification for HPV-Associated Oropharynx Cancer

By

Barbara Burtness, MD

November 25, 2014

The Eastern Cooperative Oncology Group (ECOG) conducted a trial to investigate whether treatment deintensification was feasible in patients with HPV-associated cancer.

Head and Neck Cancer